Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib and Bosutinib in CML
NCT02782403Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of axitinib in chronic myeloid leukemia (CML) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Major Cytogenetic Response up to 4 years, Recommended Phase II Dose up to 4 years and 1 more. Started Mar 2017; status: terminated.
02
Drugs
axitinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02782403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782403.